Web Results

en.wikipedia.org/wiki/Miglustat

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...

www.drugbank.ca/drugs/DB00419

Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most ...

www.ncbi.nlm.nih.gov/pubmed/24338084

Miglustat (Zavesca®, Brazaves®), a small iminosugar molecule that reversibly inhibits glycosphingolipid synthesis, is the only disease-specific drug approved ...

pubchem.ncbi.nlm.nih.gov/compound/Miglustat

Miglustat is a synthetic, N-alkylated imino analogue of D-glucose. Miglustat competitively and reversibly binds to and inhibits the activity of UDP-glucose ...

medlineplus.gov/druginfo/meds/a604015.html

Apr 15, 2016 ... Miglustat: learn about side effects, dosage, special precautions, and more on MedlinePlus.

www.medicines.org.uk/emc/medicine/13933

Oct 12, 2017 ... Zavesca (miglustat) 100 mg hard capsules - Summary of Product Characteristics (SPC) by Actelion Pharmaceuticals UK Ltd.

www.rxlist.com/zavesca-drug.htm

Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...

www1.actelion.com/documents/en-rebranded/our-products/zavesca-smpc.pdf

Pharmacokinetic data indicate increased systemic exposure to miglustat in patients with renal impairment. In patients with an adjusted creatinine clearance of ...

www.zavesca.com